Sign In
Buy ILMN
$170.93
+8.38 (+5.16%)
At Close: Jun 03, 2026
Illumina and NVIDIA collaborate to decode biology and propel precision health
09:01am, Monday, 13'th Jan 2025
Collaboration combines Illumina's sequencing technologies and Illumina Connected Software with NVIDIA tools to develop biological foundation models SAN DIEGO , Jan. 13, 2025 /PRNewswire/ -- Illumina,
Truveta sells stakes to Regeneron, Illumina in deal to build genetic database
06:07am, Monday, 13'th Jan 2025
Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals , Illumina and 17 U.S. health systems will take a $320 million stake in the company as part of a deal to build the w
Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples
03:01am, Monday, 13'th Jan 2025
Study will generate a key reference data set with Illumina Protein Prep solution SAN DIEGO , Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-ba
Illumina to Announce Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 6, 2025
04:22pm, Thursday, 09'th Jan 2025
SAN DIEGO , Jan. 9, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2024 following the close of market on Thursday, Fe
ILMN Stock Set to Gain From Latest Updates to the NovaSeq X Series
08:11am, Wednesday, 08'th Jan 2025
Illumina advances NovaSeq X Series with a software upgrade and the new 25B 100-cycle and 200-cycle kits.
Software upgrade advances complete workflow solutions New NovaSeq X 25B 100-cycle and 200-cycle kits enhance multiomic capabilities on NovaSeq X, and enable newly released Illumina Single-Cell Prep SA
Grail: What Lies Ahead After the Illumina Spin-Off
07:00am, Tuesday, 24'th Dec 2024
This spotlight on the ROBO Global Healthcare Technology and Innovation Index highlights Grail (GRAL), a standout within the Genomics subsector. It is a key component of the $53.6 million ROBO Global H
Ovation.io and Illumina Collaborate to Advance Genomic Data Research
09:13am, Tuesday, 17'th Dec 2024
PORTLAND, Maine--(BUSINESS WIRE)--Ovation.io, Inc., an organization dedicated to building best in class multi-omics datasets, today announced a collaboration with Illumina, Inc. (NASDAQ: ILMN), a glob
11 Ultra SWAN Bargains That Could Thrive As The Market Soars To Record Highs
07:00am, Thursday, 05'th Dec 2024
The S&P is up 27% in 2024, including a 5.5% rally in November. The Euphoria index is at record highs, indicating investor sentiment is extremely bullish. While 2025 is likely to see much larger volati
Illumina To Webcast Upcoming Investor Conference
04:07pm, Wednesday, 04'th Dec 2024
SAN DIEGO , Dec. 4, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 43rd Annual J.P. Morgan Healthcare Con
Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications
03:30am, Wednesday, 04'th Dec 2024
Agreement grants access to Synaffix patent portfolio related to metal-free click chemistry Technology to be used in Illumina's next-generation sequencing (NGS) products AMSTERDAM , Dec. 4, 2024 /PRNew
Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
04:41pm, Tuesday, 03'rd Dec 2024
Illumina, Inc. (NASDAQ:ILMN ) Annual Evercore ISI HealthCONx Healthcare Conference December 3, 2024 9:00 AM ET Company Participants Ankur Dhingra - CFO Sallilyn Schwartz - VP of Investor Relations Con
Myriad Genetics announces incorporation of its proprietary HRD platform in Illumina's updated comprehensive gene panel assay, TruSight™ Oncology 500 v2.
Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Wolfe Research 2024 Healthcare Conference (Transcript)
02:09pm, Wednesday, 20'th Nov 2024
Illumina, Inc. (NASDAQ:ILMN ) Wolfe Research 2024 Healthcare Conference Call November 20, 2024 9:20 AM ET Company Participants Ankur Dhingra - Chief Financial Officer Conference Call Participants Doug
ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio
08:11am, Wednesday, 20'th Nov 2024
Illumina's new TSO 500 v2 assay aims to enable CGP of tumors, bolstering its TruSight Oncology portfolio.
